Table 2 Treatment employed in 135 metaplastic breast cancer patients
Treatment modality | n (%) |
|---|---|
Surgery type | |
MRM | 80 (59.3) |
BCS | 39 (28.9) |
Palliative mastectomy | 6 (4.4) |
No surgery | 10 (7.4) |
NACT | |
Yes | 41 (30.4) |
No | 94 (69.8) |
aNACT type (n = 41) | |
Comb. anthracycline & taxanes | 27 (65.0) |
Anthracycline only | 11(26.8) |
Platinum-containing regimen | 4 (9.7) |
Others | 1 (2.4) |
Pathologic Response to NACT(n = 41) | |
RCB-0 | 3 (7.3) |
RCB-I | 3 (7.3) |
RCB-II | 14 (34.1) |
RCB-III | 20 (48.9) |
Unknown | 1 (2.4) |
ACT | |
Yes | 80 (59.3) |
No | 55 (40.7) |
ACT type (n = 80) | |
Comb. anthracycline and taxanes | 40 (50.0) |
Anthracycline only | 20 (25.0) |
Taxanes only | 14 (17.5) |
Capecitabine | 5 (6.25) |
Others | 1 (1.25) |
Adjuvant trastuzumab for HER2+ cases (n = 19) | |
Yes | 14 (73.7) |
No | 5 (26.3) |
Adjuvant hormonal for luminal cases (n = 32) | |
Yes | 30 (93.7) |
No | 2 (6.3) |
Adjuvant hormonal type (n = 30) | |
Tam | 19 (63.3) |
AI | 9 (30) |
Tam followed by AI | 2 (6.7) |
Adjuvant radiation therapy (n = 119) | |
Yes | 94 (79) |
No | 25 (21) |